|
Ym Biosciences Announces Schedule Of Nimotuzumab Presentations At ASCO 2008 Annual Meeting
06.05.2008 11:43, Medical Technology, YM BioSciences Inc. ...describing research conducted on its anti-cancer drug nimotuzumab are scheduled to be presented at the 2008 American Society of Clinical Oncology ASCO Annual Meeting which... Ym Biosciences Reports Nimotuzumab Nsclc Clinical Data at Asco Annual Meeting
02.06.2008 15:30, Medical Technology, YM BioSciences Inc. ...overall safety data from its escalating dose trial of nimotuzumab were presented in a poster presentation on June 1st 2008 at the Annual Meeting of the American Society of... Nimotuzumab clinical data presented at Asco annual meeting
03.06.2008 09:34, Medical Technology, YM BioSciences Inc. ...from three clinical trials of its anti-cancer drug nimotuzumab a humanized monoclonal antibody that targets the epidermal growth factor receptor were presented at the 2008... Ym Biosciences Reports Phase II Data For Nimotuzumab in Metastatic Colorectal Cancer
05.08.2008 12:01, Medical Technology, YM BioSciences Inc. ...from its open-label Phase II study YMB1000-015 of nimotuzumab in patients with irinotecan-refractory metastatic colorectal cancermCRC. The data are based on 58 evaluable patients... YM BIOSCIENCES reports fiscal third quarter 2008 operational and financial results
09.05.2008 16:31, Finances / Balance sheet, YM BioSciences Inc. ...2008.
"During the quarter we continued to advance nimotuzumab globally leveraging co-operative efforts of multiple partners and other licensees of the drug," said David... YM BioSciences to present at the Canaccord Adams` 28th Global Growth Conference
12.08.2008 09:04, Company-Internal, YM BioSciences Inc. ...include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials that AeroLEF...
|
HOMEPAGE
IT
Digital Press Room
back to homepage